Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses: 2022-2025

Historic Other Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $566,000.

  • Corvus Pharmaceuticals' Other Accumulated Expenses rose 40.80% to $566,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $566,000, marking a year-over-year increase of 40.80%. This contributed to the annual value of $289,000 for FY2024, which is 17.96% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Other Accumulated Expenses stood at $566,000, which was up 63.58% from $346,000 recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Other Accumulated Expenses peaked at $566,000 during Q3 2025, and registered a low of $131,000 during Q2 2022.
  • Its 3-year average for Other Accumulated Expenses is $302,818, with a median of $289,000 in 2024.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Other Accumulated Expenses soared by 85.78% in 2023 and then crashed by 52.77% in 2024.
  • Corvus Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $158,000 in 2022, then surged by 55.06% to $245,000 in 2023, then increased by 17.96% to $289,000 in 2024, then soared by 40.80% to $566,000 in 2025.
  • Its Other Accumulated Expenses stands at $566,000 for Q3 2025, versus $346,000 for Q2 2025 and $296,000 for Q1 2025.